Home / Medicines for the treatment of diseases of the cardiovascular system / The Sartan for the treatment of hypertension

The Sartan for the treatment of hypertension

Sartana – are drugs, which are recommended to be taken first in case of arterial hypertension, together with beta-blockers and calcium antagonists. These drugs repeatedly have demonstrated effectiveness with high blood pressure, and they prevent or delay damage to internal organs, decreased the probability of death.

Patients who are prescribed Sartan

Young patients suffering from arterial hypertension who have the angiotensin system activity is elevated is recommended to prescribe such drugs. Sartana also often prescribed to diabetics as they have a very pronounced organ protective properties:

  • Pronounced effect on the prevention of hypertrophy of the left ventricle.
  • Reduced the degree of microalbuminuria in diabetic nephropathy.
  • Increases the likelihood of retention of sinus rhythm in patients with persistent form of the arrhythmia.

Recently a list of patients who are allowed treatment sortname, expands.

The effectiveness of sartans

After a number of studies have shown that the Sartan effectively reduce blood pressure, taken in sufficient dosage. The effectiveness of these drugs is comparable to sortname:

  • enalapril,
  • irbesartan,
  • atenolol,
  • the amlodipine.

Drugs that combine well with sartname

These drugs combined with almost any medication to fight HELL, but the most effective treatment is observed when taking together with calcium antagonists or diuretics. Pharmacies represent to the sale of antagonists of receptors of angiotensin (ARA or Sartana) in the composition with diuretics hydrochlorthiazide.

Such a combination of drugs meet certain important requirements:

  • during the application of the combined treatment markedly increases the efficiency. This is achieved by the use of different mechanisms and effects on specific stages of pathogenesis;
  • side effects are minimized. This is possible thanks to the reduction of the dose of different components.

Proven that taken from the patient dose depends on blood pressure. What specific effects will depend on the size of the dose, was trying to figure out scientists during the study, which is referred to as IRMA 2. Experts have found that the reduction of microalbuminuria during the application irbesartan pronounced, if a person took 300 milligrams per day. The risk of reducing the development of proteinuria was significantly reduced compared with the dose of 150 milligrams per day. Thus during the reception of Aprovel dose of 300 milligrams can significantly reduce the progression of the disease andthe emergence of microalbuminuria.

The study also revealed an important factor: during the reception of cordarone irbesartan at the dose of 300 milligrams conjunction with basic therapy heart patient with persistent atrial fibrillation maintained sinus rhythm after cardioversion of conduct. The increased dose was compared with dose, 150 milligrams, adopted for the day.

Increased doses of the drug and risk of side effects

Many will ask: can there be any side effects when used by the patient a double dose of the drug irbesartan? Scientists have conducted a number of studies that have shown that the occurrence of the frequent side effects associated with increasing doses of these drugs. From here it is possible to conclude that increased doses lead to lower blood pressure, avoiding increase in the frequency and unwanted side effects from medicines.

In the study RAPiHD patients with arterial hypertension, with diastereoisomerism pressure more than 110 mmHg of applied therapy with the combined use of drugs (GHTS + irbesartan) helped to achieve good blood pressure almost 50 percent of patients. With all this, these people have the treatment led to a significant reduction in arterial blood pressure in a short time. It is very important for prediction while plan treatment of the patient. In an additional study, called VALUE revealed that the decrease in blood pressure in the short term for patients-cores showed a good result after completion of treatment.

The combined therapeutic treatment, resorting to Co-irbesartana allowed doctors and patients to make progress in the fight against high blood pressure. Open-label study called the INCLUSIVE, which was attended by more than thousands of patients and used a combined treatment, demonstrated that 80% of patients people blood pressure decreased to the desired results. When alternative methods of treatment, the number of people who managed to achieve the desired result, was only 40 percent. Last it became clear, through research, named PAMELA.

After analyzing survey data from the program INCLUSIVE, the scientists were able to conclude that the finished dosage form (HYDROCHLOROTHIAZIDE and irbesartan) allow patients and their treating doctors to make significant and desirable reduction in blood pressure in people of different age categories.